Bo-Jie Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo-Jie Tang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chunxin Lei
Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China
2 shared publications - Jia-Qi Chen
Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China
2 shared publications - Jing Luo
National Center for Integrative Medicine, Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People’s Republic of China
2 shared publications - Qingwen Tao
National Center for Integrative Medicine, Department of TCM Rheumatism, China-Japan Friendship Hospital, Beijing, People’s Republic of China
2 shared publications - Xiya Zhang
Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China
2 shared publications - Xuan-Yi Zhou
Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China
2 shared publications
Latest Publications
- 22 September 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 164
Association of clinical-immunologic clusters and anti-RNP/Ro52 antibody profiles with prognostic trajectories in primary Sjögren's disease
- 22 September 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 164
Association of clinical-immunologic clusters and anti-RNP/Ro52 antibody profiles with prognostic trajectories in primary Sjögren's disease
- Open Access
- 11 May 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Triglyceride–glucose index and anti-Ro52 antibody for identification of cardiovascular disease in patients with primary Sjögren’s disease
Primary Sjögren's disease (pSjD) confers a markedly elevated risk for developing CVD, an important contributor to mortality in this population. This study was designed to identify factors associated with CVD in pSjD and to develop a classification model. In this cross-sectional analysis of pSjD individuals (2013-2023), multivariable logistic regression was used to identify CVD-related factors. A classification model was constructed with variable selection via LASSO regression and the Boruta algorithm. Among 734 patients with pSjD, 192 (26.2%) had CVD. Age (odds ratio [OR]: 1.06, P < 0.001), body mass index (BMI; OR: 1.14, P < 0.001), triglyceride-glucose (TyG) index (OR: 3.49, P < 0.001), and positive anti-Ro52 status (OR: 1.58, P = 0.022) were independent correlates of CVD in pSjD. Moreover, age, BMI, and TyG index showed a trend of gradually increasing CVD risk in patients with pSjD (P < 0.05). A five-variable classification model incorporating age, BMI, TyG index, anti-Ro52 antibody, and corrected QT interval was developed to identify CVD status. Good discrimination (area under the curve: 0.768), proper calibration, and clinical applicability were observed for this model. Its performance remained robust upon internal validation and testing in the test set (area under the curve: 0.753 and 0.821). The TyG index and anti-Ro52 antibody serve as significant factors associated with prevalent CVD in patients with pSjD. A novel classification model that integrates these biomarkers with age, BMI, and corrected QT interval showed good performance and generalizability, and may provide a practical tool for identifying cardiovascular status in this population.
- 11 May 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Open AccessTriglyceride–glucose index and anti-Ro52 antibody for identification of cardiovascular disease in patients with primary Sjögren’s disease
Primary Sjögren's disease (pSjD) confers a markedly elevated risk for developing CVD, an important contributor to mortality in this population. This study was designed to identify factors associated with CVD in pSjD and to develop a classification model. In this cross-sectional analysis of pSjD individuals (2013-2023), multivariable logistic regression was used to identify CVD-related factors. A classification model was constructed with variable selection via LASSO regression and the Boruta algorithm. Among 734 patients with pSjD, 192 (26.2%) had CVD. Age (odds ratio [OR]: 1.06, P < 0.001), body mass index (BMI; OR: 1.14, P < 0.001), triglyceride-glucose (TyG) index (OR: 3.49, P < 0.001), and positive anti-Ro52 status (OR: 1.58, P = 0.022) were independent correlates of CVD in pSjD. Moreover, age, BMI, and TyG index showed a trend of gradually increasing CVD risk in patients with pSjD (P < 0.05). A five-variable classification model incorporating age, BMI, TyG index, anti-Ro52 antibody, and corrected QT interval was developed to identify CVD status. Good discrimination (area under the curve: 0.768), proper calibration, and clinical applicability were observed for this model. Its performance remained robust upon internal validation and testing in the test set (area under the curve: 0.753 and 0.821). The TyG index and anti-Ro52 antibody serve as significant factors associated with prevalent CVD in patients with pSjD. A novel classification model that integrates these biomarkers with age, BMI, and corrected QT interval showed good performance and generalizability, and may provide a practical tool for identifying cardiovascular status in this population.